CIK 0001711279
- Large accelerated filer
Krystal Biotech, Inc.
Sign in to watch- Ticker
- KRYS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 821080209
- Phone
- +1 412-586-5830
- Business address
- 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $17,966,069
- in 2 filings, $18.0M under 10b5-1 plans
Net −$17,966,069. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-09 | ORTH ANDREW C. Chief Commercial Officer | Exercise or conversion 10b5-1 | +12,500 | $63.55 | $794K | 12,600 |
| 2023-06-09 | ORTH ANDREW C. Chief Commercial Officer | Sale 10b5-1 | −5,261 | $128.10 | $674K | 7,339 |
| 2023-06-09 | ORTH ANDREW C. Chief Commercial Officer | Sale 10b5-1 | −6,906 | $128.94 | $890K | 433 |
| 2023-06-09 | ORTH ANDREW C. Chief Commercial Officer | Sale 10b5-1 | −333 | $129.70 | $43K | 100 |
| 2023-06-09 | ORTH ANDREW C. Chief Commercial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −12,500 | 37,500 | ||
| 2023-02-28 | ORTH ANDREW C. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-02-28 | ORTH ANDREW C. Chief Commercial Officer | Grant or award · Performance Stock Units | +10,000 | 10,000 | ||
| 2022-02-28 | ORTH ANDREW C. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2021-05-31 | ORTH ANDREW C. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +205,000 | 205,000 |
Page 1 of 1 · 9 trades